Solvay Pharmaceuticals wants to accelerate sustainable profitable growth and to provide patients with faster access to important medications. We have a strategy of expansion through targeted acquisitions. With the successful acquisition of Neopharma and its Parkinson’s medication Duodopa® we reinforced our activities in the field of Parkinson’s disease. With this acquisition and its own research, Solvay will be able to provide remedies to millions of Parkinson’s sufferers across the world, at every stage of the disease.

In general to be successful in a territory Solvay Pharmaceuticals sets up its own branch office or legal entity there. In most cases we prefer to acquire a running company and then convert it into a Solvay Pharma selling organization. But we may also start with a local agency or a host-partner relationship and build it up. Our acquisition of the Mexican pharmaceuticals company Italmex reflects our intention to expand in Latin America, and particularly Mexico, which represents 40% of all pharmaceuticals sales in Latin America. This targeted acquisition follows the acquisition, in 2000, of Brazilian company Sintofarma (now Solvay Farma).